TY - JOUR
T1 - Choice of androgen receptor pathway inhibitors (ARPi) by disease volume and timing of metastases in metastatic hormone sensitive prostate cancer (mHSPC).
JO - Journal of Clinical Oncology
UR - https://doi.org/10.1200/jco.2025.43.5_suppl.184
PY - 2025/02/10
AU - Naqvi SAA
AU - Faisal KS
AU - Khakwani KZR
AU - Childs DS
AU - Orme J
AU - Andrews J
AU - Ravi P
AU - Hussain SA
AU - Agarwal N
AU - Singh P
AU - Zakharia Y et al
ED -
DO - DOI: 10.1200/jco.2025.43.5_suppl.184
PB - American Society of Clinical Oncology (ASCO)
VL - 43
IS - 5_suppl
SP - 184
EP - 184
Y2 - 2025/07/20
ER -